EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study)

Konstantinopoulos, P. A. et al. (2022) EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study). Future Oncology, 18(31), pp. 3481-3492. (doi: 10.2217/fon-2022-0666) (PMID:36066851)

[img] Text
278801.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

2MB

Abstract

Patients with platinum-resistant or -refractory high-grade serous ovarian cancer (HGSOC) have a poor prognosis, and their management represents a substantial unmet medical need. Preclinical data and results from a phase Ib trial demonstrated the efficacy and tolerability of the combination of the α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib plus the poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib in platinum-resistant, non-BRCA-mutated ovarian cancer. Here, we describe the study design and rationale for the phase III, multicenter, open-label, randomized, active-controlled EPIK-O/ENGOT-OV61 trial investigating alpelisib in combination with olaparib compared with standard-of-care chemotherapy in patients with platinum-resistant or -refractory HGSOC with no germline BRCA mutation. Progression-free survival (blinded independent review committee) is the primary end point. Overall survival is a key secondary end point.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Glasspool, Dr Rosalind
Authors: Konstantinopoulos, P. A., Gonzalez-Martin, A., Cruz, F. M., Friedlander, M., Glasspool, R., Lorusso, D., Marth, C., Monk, B. J., Kim, J.-W., Hinson, P., Ajipa, O., Pretre, V., Han, Y., and Matulonis, U. A.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Future Oncology
Publisher:Future Medicine
ISSN:1479-6694
ISSN (Online):1744-8301
Published Online:06 September 2022
Copyright Holders:Copyright © 2022 The Authors
First Published:First published in Future Oncology 18(31): 3481-3492
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record